DYNAMIC GROUP: GLP-1 import refusal records
Has FDA refused imports of GLP-1 products from DYNAMIC GROUP?
Yes. FDA’s import refusal records list 1 refused shipment line declared as made by DYNAMIC GROUP (Canada) whose FDA product code names tirzepatide, on May 19, 2025. 1 of them carry a product code that FDA’s Import Alert 66-80 lists as a GLP-1 API or powder form.
- Country
- Canada
- City in FDA records
- Laval
- FEI numbers on the lines
- 3037657891
- Refused lines
- 1
- Lines with an Import Alert 66-80 API or powder code
- 1
- Drugs named in the product codes
- Tirzepatide
- Refusal dates
- May 19, 2025
The declared manufacturer is the firm named on the import entry. A refusal is FDA’s decision on one shipment line; it is not a finding about the firm’s other products.
Import Alert 66-80’s Green List (published Oct 9, 2026) prints a redaction in place of every firm name, so this index cannot say whether DYNAMIC GROUP is on it.
Refused shipment lines
| FDA refusal charges | Shipment ID | ||||
|---|---|---|---|---|---|
| May 19, 2025 | Canada | 61PCR74 TIRZEPATIDE (ANTI-DIABETIC) | NonSterile Powder | UNAPPROVED: The article is subject to refusal of admission pursuant to Section 801(a)(3) in that it appears to be a new drug within the meaning of Section 201(p) without an approved New Drug Application (NDA). NOT LISTED: The article is subject to refusal of admission pursuant to section 801(a)(3) of the FD&C Act in that it appears to be misbranded as defined in section 502(o) of the FD&C Act. Based on the information available to the FDA, it appears that the drug or device is not included in a list required by Section 510(j), or a notice or other information respecting it was not provided as required by 510(j) or 510(k). DIRSEXMPT: The article is subject to refusal of admission pursuant to Section 801(a)(3) in that it appears to be a drug within the meaning of Section 201(g) and it lacks adequate directions for use. | SCS-0245881-3/13/1C |
FDA refusal charges on these lines
A line can carry several charges. Text is FDA’s charge statement, verbatim.
| NOT LISTED: The article is subject to refusal of admission pursuant to section 801(a)(3) of the FD&C Act in that it appears to be misbranded as defined in section 502(o) of the FD&C Act. Based on the information available to the FDA, it appears that the drug or device is not included in a list required by Section 510(j), or a notice or other information respecting it was not provided as required by 510(j) or 510(k). | 1 |
| DIRSEXMPT: The article is subject to refusal of admission pursuant to Section 801(a)(3) in that it appears to be a drug within the meaning of Section 201(g) and it lacks adequate directions for use. | 1 |
| UNAPPROVED: The article is subject to refusal of admission pursuant to Section 801(a)(3) in that it appears to be a new drug within the meaning of Section 201(p) without an approved New Drug Application (NDA). | 1 |
This page lists public regulatory records as published by the issuing agency. A record is not a finding by this site. A warning letter states the agency’s view at the time it was issued; companies may have responded or corrected the issue since. Follow each link for the original document and any close-out letter. Report an error or add a company response.
Sources
Records last pulled Nov 15, 2026. Every entry links to the original public record.
1 line from FDA files read Nov 15, 2026.